References
- Babu YS, Chand P, Bantia S, et al. (2000). BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482–6
- Bantia S, Arnold CS, Parker CD, et al. (2006). Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 69:39–45
- Birnkrant D, Cox E. (2009). The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 361:2204–7
- EMA. (2011). Guideline on bioanalytical method validation. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf [last accessed 22 Oct 2012]
- Gough K, Hutchison M, Keene O, et al. (1995). Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 29:1039–48
- Gubareva LV, Webster RG, Hayden FG. (2001). Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403–8
- Health Canada. (2012). Guidance document, conduct and analysis of comparative bioavailability studies. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/bio/gd_cbs_ebc_ld-eng.pdf [last accessed 16 Apr 2014]
- Kiso M, Mitamura K, Sakai-Tagawa Y, et al. (2004). Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759–65
- Kohno S, Yen MY, Cheong HJ, et al. (2011). Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir inpatients with seasonal influenza virus infection. Antimicrob Agents Chemother 55:5267–76
- Pharmaceuticals and Medical Devices Agency (PMDA). (2013). RAPIACTA® for Intravenous drip infusion. Available from: http://www.info.pmda.go.jp/go/pack/6250405A1032_1_02/ [last accessed 30 Jun 2014]
- Smith BP, Vandenhende FR, DeSante KA, et al. (2000). Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278–83
- Sorbello A, Jones SC, Carter W, et al. (2012). Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 55:1–7
- Sugaya N, Kohno S, Ishibashi T, et al. (2012). Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 56:369–77
- Swan S, Marbury T, Smith W, et al. (2009). Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment. Available from: http://www.biocryst.com/PDFs/BCRX_Peramivir_Swan_IDSA_2009_Poster.pdf [last accessed 30 Jun 2014]
- US FDA. (2001). Guidance for industry, bioanalytical method validation. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf [last accessed 3 Jul 2008]
- US FDA. (2009). Emergency use authorization of peramivir IV, fact sheet for health care providers. Available from: http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm187811.pdf [last accessed 12 Aug 2014]